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Abstract
Antibody-dependent enhancement (ADE) of infection may cause severe illness in patients 
suffering a secondary infection by a heterologous dengue virus (DENV) serotype. During ADE of 
infection, cross-reactive non- or poorly-neutralizing antibodies form infectious virus-Ab 
complexes with the newly infecting serotype and enhance virus infection by binding to the Fcγ 
receptors (FcγR) on FcγR-bearing cells. In this study, we determined that molecular determinants 
of DENV2 envelope protein critical for virus entry during non-ADE infection are also required for 
ADE infection mediated by FcγRIIA, and binding of virus-Ab complexes with FcγRIIA alone is 
not sufficient for ADE of infection. The FcγRIIA mainly plays an auxiliary role in concentrating 
the virus-Ab complex to the cell surface, and other primary cellular receptors are required for virus 
entry. Understanding the viral entry pathway in ADE of DENV infection will greatly facilitate 
rational designs of anti-viral therapeutics against severe dengue disease associated with ADE.
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Introduction
The dengue virus (DENV) serocomplex consists of 4 distinct serotypes, DENV1-4, that are 
members of genus Flavivirus in the family Flaviviridae. They are the most important 
mosquito-borne viral human pathogens, and are transmitted primarily by Aedes aegypti. A 
recent study estimated that 390 million human DENV infections occur annually and 96 
million apparent illnesses occurred in 2010 alone (Bhatt et al., 2013). All four DENV 
serotypes can cause dengue fever (DF) and the more severe form, dengue hemorrhagic fever 
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(DHF). Primary infection in patients older than one year of age usually results in 
asymptomatic or self-limited DF, and lifelong immunity against the infecting serotype 
(Halstead, 1970). However, long-term protection is not elicited against infections by other 
serotypes (heterologous DENV infections) (Halstead, 1988). Heterologous DENV infection 
of adults, or infants who have passively acquired DENV immunity from the mother, are at 
risk for severe dengue (Kliks et al., 1988). Many in vitro and in vivo experimental studies 
support antibody-dependent enhancement (ADE) of DENV infection as one of the leading 
causes of the severe dengue illness during secondary heterologous infection of humans 
(Balsitis et al., 2010; Halstead et al., 2002; Halstead, Nimmannitya, and Cohen, 1970; 
Halstead and O'Rourke, 1977; Kliks et al., 1988; Kouri et al., 1989; Sabin, 1952).
The DEN virion contains an 11-kb single-stranded, positive-sense RNA genome encoding 
three structural and seven non-structural proteins. The viral nucleocapsid, consisting of 
capsid (C) proteins complexed with the viral RNA genome, is surrounded by the viral 
envelope derived from cellular membranes containing viral membrane (M) and envelope (E) 
transmembrane proteins. The DENV E glycoprotein is responsible for host cell attachment 
and virus-mediated cell membrane fusion during virus entry. Several flaviviral E protein 
crystal structures have been solved and showed that the E monomer is composed of 3 
discontinuous β-barrel domains (Modis et al., 2003, 2004, 2005; Rey et al., 1995) designated 
domain I (DI), II (DII) and III (DIII), and 180 E monomers are arranged into 90 head-to-tail 
homodimers on the surface of each virion (Kuhn et al., 2002). The DIII is believed to be 
responsible for cell attachment, as it has an immunoglobulin-like structure, which is a 
common structure of cell-adhesion proteins. Furthermore, this domain is recognized by 
strongly neutralizing monoclonal antibodies (MAbs) that block virus attachment to cells, 
and soluble recombinant DIII has been shown to block virus infection in vitro (Crill and 
Roehrig, 2001; Hiramatsu et al., 1996; Roehrig, Bolin, and Kelly, 1998; Sukupolvi-Petty et 
al., 2007).
Previous studies have demonstrated that flaviviruses enter cells mainly via receptor-
mediated clathrin-dependent endocytosis (Chu and Ng, 2004; van der Schaar et al., 2008). 
The E protein on virion surfaces attaches to extracellular matrix or plasma membrane 
receptors such as sulfated glycosaminoglycans (Chen et al., 1997), DC-SIGN (Navarro-
Sanchez et al., 2003; Pokidysheva et al., 2006), and/or other unidentified cell surface 
molecules. The cell-attached virion is then localized to clathrin-coated pits and transported 
into endosomes. Once the endosome is acidified, the molecular hinge at the junction of DI 
and DII triggers a conformational rearrangement of E proteins from homodimers to 
homotrimers on the virion surface and a co-localization of the fusion loops in DII of the 
homotrimers. The homotrimer fusion loops then insert into the endosomal membrane, 
resulting in viral-endosomal membrane fusion, release of viral nucleocapsid, and initiation 
of viral replication (Modis et al., 2004).
Although the early events in non-ADE DENV infection have been studied in vitro, the entry 
pathway of antibody-coated virus and the molecular basis of ADE of DENV infection have 
not been determined. It is believed that pre-existing non- or sub-neutralizing levels of cross-
reactive antibodies (Abs) raised during a previous DENV infection bind to the newly 
infecting heterologous serotype virus, enhancing infection of FcγR-bearing myeloid cells 
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such as monocytes and macrophages. Association of the DENV-Ab complex with FcγR on 
these cells leads to an increased number of infected cells (extrinsic ADE) as well as 
suppression of innate immunity, resulting in enhanced virus output by infected cells 
(intrinsic ADE) (Halstead et al., 2010). In vitro studies have demonstrated that both FcγRIA 
and FcγRIIA can mediate enhanced DENV infection (Kontny et al, 1988; Littaua et al., 
1990, Mady et al., 1991); however, these receptors appeared to utilize different DENV-Ab 
internalization mechanisms. The infectivity of immune complexes is greater upon binding to 
FcγRIIA than to FcγRIA (Rodrigo et al., 2006, 2009). The DENV-Ab entry mechanism via 
FcγR binding is still unknown, but there are at least two possible entry models: (1) the Ab-
opsonized DENV may directly internalize into cells by phagocytosis after binding to the 
FcγR; or (2) the FcγR may play a role in concentrating DENV-Ab complexes on the cell 
surface, but interaction with other cellular receptors is still required for successful complex 
internalization and infection (Mady et al., 1991). Following internalization of the DENV-Ab 
complex via FcγR-binding, it is not clear whether viral E protein-mediated membrane fusion 
similar to that in the non-ADE DENV entry pathway is also required to release viral 
nucleocapsid for replication.
In this study, we used several DENV2 E protein mutants to identify molecular determinants 
critical for virus-immune complex entry via ADE of DENV infection of FcγRIIA-bearing 
human myelogenous K562 cells and monkey CV-1 fibroblasts constitutively expressing 
transfected human FcγRIIA. Previously we used these mutants to identify critical 
determinants in the early events of non-ADE virus entry into several cell lines (Butrapet et 
al., 2011; Erb et al., 2010; Huang et al., 2010; Roehrig et al., 2013). Mutants included in this 
study bear mutations at critical motifs involved in receptor binding or virus-mediated 
membrane fusion during non-ADE infection by DENV2. Through identification of the 
DENV E protein determinants for both types of infection, we further elucidated the virus-Ab 
complex entry mechanism.
Results
Optimization of the in vitro ADE assay
All ADE assays in this study were conducted with the same lot of MAb 4G2. The MAb was 
serially diluted to determine its optimal concentration for ADE of wild-type (WT) DENV2 
infection in K562 cells at 3 different MOIs, and enhancement of infection was measured by 
increased vRNA production (Fig 1A). At both MOIs of 1 and 0.2, enhancement (at least 2-
fold higher vRNA than that of non-ADE infection control) was achieved at 1:2,000-1:4,000 
dilutions of MAb 4G2. At MOI of 0.01, the enhancement was observed between 1:4,000 and 
1:20,000 dilutions. Although 1:40,000 dilution also resulted in 2-fold higher mean titer than 
the non-ADE virus infection control, it was excluded due to its higher standard deviation. 
Based on the titration results, 1:4,000 dilution of 4G2 was selected for optimization of the 
ADE assay using fluorescence-activated cell scanning (FACS) analysis to measure 
enhancement of cell infection rates. Cells infected by WT DENV2 at different MOIs (0.01, 
0.1, 0.5, and 1.0) pre-incubated with 4G2 at 1:4000 dilution showed obvious ADE as 
measured by FACS analysis of virus-infected cells, and Fig. 1B shows the results with 
MOI=0.5 as a representative example.
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Although 1:4,000 dilution of 4G2 was found to result in consistent enhancement effect at a 
wide range of MOI, the peak enhancement day was delayed in the cells infected with lower 
MOIs. The peak enhancement days of infection (measured by FACS) with WT DENV2 at 
MOI of 0.5, 0.1 and 0.01 were days 2, 3 and 4 post infection (pi), respectively, and the 
enhancement effect became undistinguishable from the non-ADE infection rapidly after the 
peak day. This is expected, as the enhancing MAb was only present in the initial virus-Ab 
infection of the cells and subsequent virus infection cycles in the culture were in non-ADE 
conditions, thereby the initial enhancement effect was eventually masked by the later non-
ADE cycles. Due to the time-dependent nature of the assay, it was ideal to conduct the ADE 
assay at high MOI and analyze samples as soon as the viral antigens in the infected cells 
reached the FACS detectable level. Therefore, we conducted most of the following 
experiments at MOI = 0.5. However, two of the DENV2 mutants in the study are 
replication-defective and cannot yield sufficient titers to support such high MOI. Therefore, 
lower MOIs (0.01 or 0.1) were used for experiments with those mutants. To compensate for 
the slower replication characteristics of all tested DENV2 mutants, we extended our assays 
for 1 to 2 additional days after the WT-ADE peak day to ensure detection of potentially 
delayed enhancement kinetics. In addition, WT DENV2 was included as the positive ADE 
control in every experiment at the same MOI as each mutant to ensure all the experimental 
conditions could successfully detect ADE.
To confirm that the enhanced infection was Ab-dependent, we used a 4G2-epitope knockout 
mutant, G106L, in the ADE assay. Mutant G106L was engineered with a G to L substitution 
at AA 106 within the fusion loop (Huang et al., 2010). Although this mutant is fusion-
competent and infectious, it has lost the capacity to bind to 4G2. Unlike the 4G2-opsonized 
WT virus, pre-incubation of mutant G106L with 4G2 did not result in enhancement of cell 
infection between 2 and 4 days pi (Fig. 1C), confirming that enhanced infection requires 
binding of 4G2 to DENV2.
The lysine 305, 307 and 310 cluster but not the FG loop on DIII is critical for both ADE and 
non-ADE infections of K562 cells
Two E DIII mutant DENV2, VEPGΔ and KKK305/307/310EEE, bearing deletions or 
substitutions at putative receptor binding sites (Erb et al, 2010; Roehrig et al, 2013) were 
chosen for this study (Table 1 and Fig. 2). The VEPGΔ mutant has a deletion of the FG loop 
(AA 382-385) between strands F and G on the lateral ridge of DIII. We infected K562 cells 
with mutant VEPGΔ or WT DENV2 at MOI of 0.5 with or without enhancing 4G2 pre-
incubation (Fig. 3A). Results showed that without 4G2, the proportion of mutant VEPGΔ-
infected cells was similar to that of WT virus-infected cells on day 2 pi, but the mutant 
showed a somewhat lower infection rate than the WT virus by day 3 pi. This result was 
consistent with our previous observation that deletion of the FG loop impaired virus 
replication efficiency in mammalian cells (Erb et al., 2010). When mutant VEPGΔ was 
opsonized with enhancing 4G2, a significant increase in infected cells compared to non-
ADE infections was observed on both days 2 and 3. This positive ADE effect was also 
confirmed by measuring the extracellular vRNA levels by qRT-PCR (data not shown).
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Mutant KKK305/307/310EEE, bearing K to E substitutions at residues 305, 307, and 310 on 
the A strand of DIII, is infectious in mosquito C6/36 cells but not in Vero cells (Table 1) 
(Roehrig et al., 2013). In this study, we found that this triple mutant did not grow in K562 
cells in the absence of 4G2, and 4G2-opsonization of the mutant failed to rescue infectivity 
(Fig. 3B). The results were also confirmed by the lack of increase in extracellular vRNA 
levels during the 5-day infection period (data not shown). Because the triple mutations may 
have significantly altered the E protein structure, this could potentially affect nearby or even 
distant Ab epitopes, such as the 4G2 epitope. To confirm that the failure of 4G2-ADE 
infection was not due to the loss of 4G2 binding capacity of this mutant, we conducted an 
immunofluorescence assay (IFA) of virus-infected C6/36 cells with 2-fold serial dilutions of 
4G2. The results demonstrated that both mutant KKK305/307/310EEE and WT DENV2 
infected cells bound the MAb to similar titration endpoints, suggesting that the triple mutant 
E protein retained similar 4G2-binding capacity to the WT DENV2 (Table 1). Using C6/36 
cells in a neutralization assay, we also confirmed that 4G2 can effectively neutralize both 
WT and the triple mutant viruses (data not shown), suggesting the binding between 4G2 and 
triple mutant was fully functional.
Virus-mediated membrane fusion is required for ADE infection of K562 cells
Two temperature-sensitive fusion-defective mutants, G104S and L135G (Table 1 and Fig. 
2), were investigated to determine whether ADE infection requires competent viral fusion 
activity. The G104S mutation resides within the cd loop of DII that is known to be the 
fusion loop. The L135G mutation occurs in the E0 loop (hinge-2 peptide) that is part of the 
molecular hinge between DI and DII. These two mutants were fusion-defective and not 
infectious in Vero cells at 37°C, but became infectious at 28°C (Huang et al., 2010; Butrapet 
et al., 2011). As expected, we observed that both mutants were also temperature-sensitive in 
K562 cells; they did not replicate in the cells at 37°C, but grew as well as WT DENV2 in 
K526 cells at 28°C (Fig. 4). The temperature-sensitivities of these mutants were reversible, 
since pre-incubation of the mutants at 37°C (with or without 4G2) did not block subsequent 
viral replication after culture temperatures were lowered to 28°C (Fig. 4C and 4E). This 
property allowed us to study the mutants under both fusion-defective and -competent 
conditions.
Opsonization of the mutants with 4G2 did not enhance or rescue their infectivity at 37°C 
(Fig. 4A and 4D), but both 4G2-opsonized mutants exhibited ADE similar to opsonized WT 
DENV2 when infected cells were cultured at 28°C (Fig. 4B and 4E). Previously, we have 
verified that both G104S and L135G retained similar 4G2-binding capacity as WT DENV2 
when tested by IFA with viral antigens expressed in C6/36 cells cultured at 28°C (Table 1). 
Interestingly, ADE of G104S infection in K562 cells at 28°C was not observed if pre-
incubation of G104S with 4G2 was conducted at 37°C (Fig. 4C), suggesting that G104S 
failed to form a complex with 4G2 at 37°C. It has been demonstrated that the conformation 
of dengue virions differs at 37°C and 28°C (Fibriansah et al., 2013; Zhang et al., 2013). The 
4G2 epitope is located close to the fusion loop, and the G104S mutation in the fusion loop 
likely disrupted the epitope conformation required for effective 4G2 binding at 37°C. On the 
other hand, mutant L135G pre-incubated with 4G2 at 37°C showed successful infection 
enhancement after the temperature was shifted to 28°C post cell infection (Fig. 4E). All the 
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ADE assay results in Fig. 4 have also been confirmed with qRT-PCR of vRNA output (data 
not shown).
ADE of infection is not observed in CV-1 CD-32 cells
To further investigate whether expression of FcγRIIA alone sufficed for ADE infection, we 
also performed the in vitro ADE assay with WT DENV2 in the stable FcγRIIA-expressing 
CV-1 CD-32 cell line. This cell line was previously used to demonstrate that FcγRIIA can 
modulate neutralization of DENV-Ab complex infectivity (Rodrigo et al., 2009). Despite 
multiple efforts and testing various MAbs (4G2, 3H5, and 1A1D-2) that showed good 
enhancement of WT DENV2 infection in K562 cells, we were not able to detect any ADE of 
WT DENV2 infection in the CV-1 CD32 cells (data not shown). Instead, virus neutralization 
was demonstrated at all dilutions of the MAbs. We observed that the CV-1 CD32 cell 
infection rate by the WT virus without Ab was significantly lower than that typically 
observed in WT virus-infected K562 cells at 2 days pi. To further confirm this observation, 
we conducted three separate experiments, with 2 or 3 replicates in each experiment, to 
directly compare WT DENV2 infectivity in K562 and CV-1 CD32 cells at MOI of 0.5 
without enhancing Ab (Table 2). The results revealed that the CV-1 CD32 cells are 
significantly less susceptible (p<0.05) to DENV2 infection than K562 cells.
To investigate whether variations in the level of FcγRIIA expression on K562 and CV-1 
CD-32 cells might contribute to the differences in ADE infection, we stained FcγRIIA 
molecules on both cell types with anti-CD32-PE and measured the PE intensity by FACS. 
The geometric mean fluorescence intensity (GMFI) of stained FcγRIIA and the percentage 
of cells expressing FcγRIIA were compared. The results showed that both cell lines 
exhibited a similar proportion of cells expressing FcγRIIA, but K562 cells expressed 
significantly less FcγRIIA (lower GMFI) than CV-1 CD32 cells (Table 2). This observation 
suggested that the lack of ADE of DENV2 infection in CV-1 CD32 cells was not due to 
insufficient expression of FcγRIIA on the cell surface.
Discussion
Viral attachment and virus-mediated endosomal membrane fusion are two critical early 
events in the DENV entry pathway. Our previous mutagenesis studies in the DENV2 E 
protein have identified several functional motifs involved in these events (Butrapet et al., 
2011; Erb et al., 2010; Huang et al., 2010; Roehrig et al., 2013). In this study, for the first 
time to our knowledge, we have identified molecular determinants on the DENV2 E protein 
that are critical for virus entry during ADE infection of FcγRIIA-expressing cells by virus-
Ab complexes.
Methods for inducing and assaying ADE of infection were optimized in a constitutively 
FcγRIIA-expressing K562 cell line using flavivirus group cross-reactive MAb 4G2. Using 
mutant G106L, which lacks the epitope recognized by 4G2, we confirmed the enhancement 
effect observed in the ADE assay was Ab-dependent. We expected that a lower virus MOI 
would require greater dilutions of Ab to maintain the correct ratio between virus and Ab for 
ADE. Indeed, the dilution range of 4G2 capable of mediating ADE of DENV2 infection at 
MOI of 0.01 was somewhat higher than that for higher MOIs. However, we found that the 
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same 1:4000 dilution of 4G2 can effectively induce ADE of WT DENV2 infection at all the 
various MOIs (0.01 – 1.0) we tested (Figs.1, 3, and 4).
The FG loop of E DIII has long been proposed to be a major receptor-binding domain for 
mosquito cells, because it is unique for mosquito-borne flaviviruses (Rey et al., 1995) and 
recognized by several strongly-neutralizing Abs (Gromowski and Barrett, 2007; Hiramatsu 
et al., 1996). VEPG is the serotype-specific AA sequence of the FG loop for DENV2. Using 
mutant VEPG? virus, we previously demonstrated that the FG loop is dispensable for 
infection of C6/36 cells, but important for effective viral midgut infection and dissemination 
in Ae. aegypti mosquitoes (Erb et al., 2010). We also showed that deletion of the FG loop 
only reduced viral replication efficiency and genetic stability in Vero cells. In this study, we 
further determined that the FG loop was not required for either ADE or non-ADE infection 
in K562 cells.
The KKK305/307/310EEE mutation was shown to be lethal in mammalian cells, including 
Vero, HepG2, and K562 cells, and the mutant virus had lower infectivity than WT virus for 
C6/36 cells (Roehrig et al., 2013). In the current study using FACS analysis, we could not 
detect nascent prM protein synthesis by MAb 2H2 staining of the infected K562 cells 3 to 5 
days pi (Fig. 3B), suggesting that blockage of the mutant infection occurred before viral 
polyprotein translation and processing. Because the triple mutant was found to be fusion 
competent (Huang et al., 2010), the blockage likely occurred before membrane fusion. This 
mutant virus was also shown to lose reactivity with several MAbs that block attachment of 
DENV2 to Vero cells (Roehrig et al., 2013);therefore, the triple K motif is likely critical for 
DENV2 attachment to mammalian cells during non-ADE infection. Since the mutant virus 
opsonized with enhancing 4G2 was able to attach to K562 cells via FcγRIIA binding, it may 
overcome its infectivity blockage if the binding leads to direct cell entry by the virus-Ab 
complex. Our results indicated, however, that 4G2-opsonization of the mutant was not 
sufficient to bypass the viral attachment defect caused by these triple mutations. Similarly, 
our previous study also showed that the N67-glycan on the E protein of the triple mutant 
virus was intact, but the interaction between the glycan and DC-SIGN, another important 
cell surface receptor involved in DENV entry of dendritic cells and macrophages, expressed 
on DC-SIGN-transformed Raji cells was not sufficient to rescue the defect of the triple K 
mutations (Roehrig et al., 2013). Taken together, these results indicated that attachment to 
other, undefined cellular receptors engaging the triple K motif is essential for DENV2 ADE 
and non-ADE infection in many mammalian cells.
The ability of DENV to escape the endosome and release its nucleocapsid into the 
cytoplasm for replication prior to lysosomal degradation is critical during virus entry via 
clathrin-mediated endocytosis in non-ADE infection. During ADE of DENV infection, 
virus-Ab complexes binding to FcγR may permit the virus-Ab to enter cells through 
phagocytosis. Because virions that enter by FcγR-mediated phagocytosis would also 
eventually enter the endosomal/lysosomal pathway, viral-endosomal membrane fusion is 
likely necessary for the infectivity of virus-Ab complexes that enter through phagocytosis 
(reviewed in Flannagan et al., 2012; Smit et al., 2011). Indeed, using 2 temperature-sensitive 
fusion mutant viruses (G104S and L135G) with mutations targeted to affect different steps 
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in fusion, we demonstrated that viral E protein conformation-mediated membrane fusion is 
critical for infectivity under both ADE and non-ADE conditions.
The CV-1 CD32 cells were previously shown to exhibit lower neutralization kinetics for 
DENV2 (required higher Ab amount to neutralize the virus) when compared to CV-1 control 
cells (CV-1 cells transfected with empty vector) (Rodrigo et al., 2009). We observed similar 
results when comparing the neutralization of WT DENV2 by 4G2 in CV-1 CD32 cells and 
in CV-1 control cells (data not shown). Clearly the interaction between DENV-Ab 
complexes and the FcγRIIA on CV-1 CD32 cells can slightly augment the infectivity of 
opsonized DENV, resulting in lower neutralization kinetics. However, ADE of WT DENV2 
infection was not observed in CV-1 CD32 cells with any of the MAbs tested, and this was 
not due to insufficient expression of FcγRIIA on the CV-1 CD32 cells. The CV-1 CD-32 
cells were less susceptible than K562 cells to WT DENV2 infection under non-ADE 
conditions, indicating that CV-1 cells may possess significantly fewer primary DENV2 
receptors than the K562 cells. This result suggested that without sufficient primary 
receptors, FcγRIIA alone was not enough to mediate detectable ADE of DENV2 infection in 
CV-1 CD-32 cells. Taken together, our results from both K562 and CV-1 CD-32 cells 
indicated that FcγRIIA may only play an auxiliary role in concentrating DENV to the cell 
surface, and other primary DENV2 receptors may be required for effective virus 
internalization during ADE of infection.
Functional domains on the E protein of DENV required for non-ADE infection have been 
actively studied, but their involvement in ADE of DENV infection has not been directly 
addressed. Such knowledge is important for development of vaccines or anti-viral 
therapeutics that are effective against both non-ADE and ADE of DENV infection. We 
provide experimental evidence that certain E protein structures essential for virus entry 
during non-ADE DENV2 infection are also indispensable for ADE infection in FcγRII-
bearing K562 cells, and the entry pathway of DENV-Ab complexes in FcγRIIA-mediated 
ADE may be similar to that of non-ADE DENV infection. This report revealed that 
prevention measures targeted to DENV entry and membrane fusion could potentially be 
effective for both types of infection. It has been demonstrated that signaling cascades 
following the binding between DENV-Ab complexes and FcγR in myeloid cell lines trigger 
innate immune responses that contribute to intrinsic ADE (Ubol et al., 2010.). However, 
signaling cascades are only critical for FcγRIA-mediated DENV-Ab infection, but not for 
FcγIIA-mediated ADE (Rodrigo et al., 2006). This study only focused on investigating 
DENV2 E protein molecular determinants involved in the extrinsic ADE mechanism, which 
is predominantly mediated by FcγRIIA. Further studies to include cells expressing FcγRIA 
(signaling competent or non-competent), and cells expressing both FcγRIA and FcγRIIA 
will be necessary to advance our understanding of ADE mechanisms of DENV infection.
Materials and Methods
Cell Cultures, Viruses, and Antibodies
The human myelogenous leukemia cell line K562, expressing Fcγ receptor IIA (FcγRIIA) 
on cell surfaces (ATCC, CCL-243), was cultured in Iscove’s Modified Dulbecco’s Medium 
(IMDM). Grivet monkey kidney CV-1 cells stably transfected to express human FcγRIIA 
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(CD32), CV-1 CD32, provided by Dr. Jacob Schlesinger at University of Rochester 
(Rodrigo et al., 2009), were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 50 mg/mL Hygromycin B (Roach). Both cell lines were cultured in medium 
supplemented with 10% fetal bovine serum (FBS) and were incubated at 37°C with 5% 
CO2.
Viruses used in this study were recombinant DENV2 derived from an infectious cDNA 
clone, pD2IC-30P-NBX, based on DENV2 strain 16681 (Huang et al., 2010; Kinney et al., 
1997). The DENV2 E mutants were previously engineered by site-directed mutagenesis 
(Butrapet et al., 2011; Erb et al., 2010; Huang et al., 2010; Roehrig et al., 2013). All viruses 
were recovered and passaged once in C6/36 cells prior to infecting K562 cells.
A single batch of each unpurified mouse MAb, 4G2 (anti-flavivirus E protein), 1A1D-2 
(anti-DENV-1, 2, and 3 E), 3H5 (anti-DENV2 E), and 2H2 (anti-DENV prM) prepared at 
CDC, DVBD, Fort Collins, CO, was used in the study. MAb 2H2 used for staining virus-
infected cells for FACS was further purified and conjugated with Alexa Fluor 488 using 
Alexa Fluor® 488 protein labeling kit (Invitrogen) following manufacturer’s protocol, and 
used for staining of de novo synthesized prM proteins within infected cells.
In vitro ADE assay
The in vitro ADE assay was conducted by infecting K562 or CV-1 CD32 cells with 
DENV2-Ab complexes in duplicate or triplicate. Viruses at MOI of 0.01 to 1 (indicated in 
each experiment) were incubated with MAbs to form DENV-Ab complexes at 37°C (unless 
otherwise specified) for 1 h prior to infection. The complexes were incubated with equal 
volume of K562 cells in a total volume of 250 µL at 37°C (unless otherwise specified) for 2 
h adsorption. Infected cells were washed twice with PBS to remove excess Ab and virus, 
and cultured in 3 mL of medium with 5% FBS at 37°C or 28° C for 2-5 days, as specified in 
each experiment. The ADE assay in CV-1 CD32 cells was performed in 6-well plates. Cells 
were inoculated with 100 µL/well of virus-Ab complex for 2 h adsorption at 37°C. After 
adsorption, cells were washed twice with DMEM or PBS before culturing in 4 mL of 
DMEM with 5% FBS and 50 mg/mL Hygromycin B.
ADE infection was compared side-by-side with infection by DENV without Ab (non-ADE 
infection; virus was pre-incubated with medium only). ADE and non-ADE infections with 
WT DENV2 30P-NBX were also included as the positive ADE control in each experiment 
to validate the success of each ADE assay. Mock infection was included as a negative 
control for each experiment and used for standardizing experiments. On the days specified 
in each experiment, culture medium and infected cells were harvested for further viral RNA 
(vRNA) quantitation and cell infection rate analysis, respectively.
Analysis of DENV infection rate
Infected cells were harvested and fixed with 250 μL of BD fixation/permeabilization 
solution (BD Biosciences) at 4°C for 20 min. Fixed cells were washed twice with BD perm/
wash buffer and incubated with human FcR binding inhibitor (eBioscience) at 4°C for 20 
min to prevent binding of Fc of the 2H2 conjugate to the FcR on the cell surface. Cells were 
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than stained with 5.1 μg/mL of 2H2-AlexaFluor-488 at a final volume of 50 µL for 1 h at 
37°C. The stained cells were washed and resuspended in 0.5-1.5 mL of BD perm/wash 
buffer for FACSCalibur flow cytometry analysis (BD Biosciences). At least 20,000 events 
were acquired for each sample, and the percent cell infection was analyzed by CellQuest Pro 
software (BD Biosciences). The mock infection sample was used to set gating parameters 
for each experiment so that the cell auto-fluorescence background was below 1%. Final 
percent cell infection results were further normalized by subtracting the auto-fluorescence 
background. The non-ADE of WT DENV infection baseline was used to carefully optimize 
infection procedure and detection sensitivity/specificity of the FACS assay, so the non-ADE 
infection baseline and the mock control background were significantly different.
Quantification of viral RNA
All of the ADE assays measured by FACS were also confirmed by qRT-PCR of vRNA 
outputs. Viral RNA was extracted from infected cell culture supernatant using the QIAamp 
viral RNA kit (Qiagen). Viral genomic equivalents were analyzed on the CFX 96 Touch™ 
Real-Time PCR Detection System (BioRad) by one-step qRT-PCR with Quantitect virus kit 
(Qiagen), DENV2 primers, and TaqMan DENV2 probe as previously described (Roehrig et 
al., 2013). Quantitative RT-PCR cycling was performed as follows: RT at 50°C, 20 min; 
95°C, 5 min for RT inactivation and hot start; 50 cycles of 95°C, 15 sec; 57°C, 1 min 15 sec. 
In vitro transcribed vRNA from a DENV2 cDNA subclone was generated and quantitated to 
make standard curves for each qRT-PCR assay as previously described (Butrapet et al., 
2006). Each sample was measured in 2 or 3 replicates.
Determination of FcγRIIA on cell surfaces
The expression of FcγRIIA (CD32) on the surfaces of K562 and CV-1 CD32 cells was 
measured by FACSCalibur flow cytometry. Uninfected cells were fixed in 100 μL of 4% 
paraformaldehyde at 4°C for 20 min. Fixed cells were washed twice with PBS and 1% FBS 
without permeabilization solution. The cells were stained with mouse anti-human CD32 
conjugated with phycoerythrin (PE) (anti-CD32-PE Ab, eBioscience) for FcγRIIA staining, 
or with mouse anti-IgG1 isotype control-PE Ab (eBioscience) for non-specific binding 
control. The percent of cells expressing FcγRIIA was calculated by subtracting the percent 
anti-IgG isotype control-PE-staining background from the percent anti-CD32-PE for each 
cell type. The geometric mean fluorescence intensity (GMFI) was also measured to compare 
the FcγRIIA expression levels between K562 and CV-1-CD32 cells. Histograms of the anti-
CD32-PE and the anti-IgG isotype control-PE from the same cell type were overlaid, and 
GMFI of stained FcγRIIA for each sample was calculated after subtracting the overlap curve 
of the IgG isotype background control. All final reported results were the average from 3 
separate experiments.
Statistics
Student’s t-test was used to test for significance and results with p<0.05 were considered 
significant.
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Fig. 1. 
ADE assay in K562 cells. (A) Titrations of MAb 4G2 for ADE of infection in K562 cells. 
Quantitation of vRNA in medium of cells infected with WT DENV2 pre-incubated with 
serial dilutions of 4G2 by qRT-PCR. Samples were collected and measured from day 2 
(MOI=0.2 and 1.0) or 3 (MOI=0.01) pi. Dotted line shows the cutoff of qRT-PCR. (B) 
FACS dot plot analysis of ADE assay with WT DENV2 (MOI=0.5). Infected K562 cells 
were harvested and stained with anti-M protein 2H2-AlexaFluor-488 on day 2 pi. Numbers 
indicate percentages of infected cells. (C) Verification of ADE assay. DENV2 WT virus and 
mutant G106L were used in the assay. Percentages of K562 cells infected with virus-4G2 
complex or virus without 4G2 were measured by FACS on days 2-4 pi. Significant 
difference (*, p <0.05) between cell infection rates with and without 4G2 of each virus were 
used to indicate positive enhancement.
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Fig. 2. 
Location of mutations introduced into DENV2 E protein. (A) Top-view of E homodimer on 
mature virion was acquired from Protein Data Bank [PDB ID: 1OAN] and rendered by 
Polyview-3D (Porollo and Meller, 2007). E protein domains I, II and III are shown in red, 
yellow and blue, respectively. The glycan chains are not shown. Locations of mutated AA 
residues are highlighted on WT DENV2 E protein as well as shown in the zoom-in images. 
Putative receptor-binding residues targeted for mutation, FG loop (382-385 VEPG), shown 
in magenta, and KKK305/307/310, shown in green. Residues targeted for fusion-defective 
mutations, G104S and L135G, are shown in cyan.
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Fig. 3. 
Percent cell infection by putative receptor-binding mutants and WT virus with and without 
enhancing MAb 4G2 in K562 cells. (A) Infection rates of VEPGD or WT DENV2 at 
MOI=0.5. (B) Infection rates of mutant KKK305/307/310EEE or WT DENV at MOI=0.01. 
Significant difference (*, p<0.05) between cell infection rates of each virus with and without 
4G2 were used to indicate positive enhancement.
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Fig. 4. 
ADE assays of temperature-sensitive fusion-defective mutants. (A to C) Percent of cells 
infected by mutant G104S or WT virus (MOI=0.5); (D and E) Percent of cells infected with 
mutant L135G or WT virus (MOI=0.1) with or without enhancing 4G2 (1:4,000). The 
temperatures indicated are incubation temperatures for virus-Ab complex formation/virus-
Ab infected cell growth. Significant difference (*, p<0.05) between cell infection rates of 
each virus with and without 4G2 were used to indicate positive enhancement.
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Table 2
Susceptibility to WT DENV2 infection and FcγRIIA expression levels on K562 and CV-1 CD32 cells
K562 CV-1 CD32
Susceptibility to WT DENV2a 7.76±0.97% 3.66±1.07%
Cells expressing FcγRIIA 60.26±7.22% 66.32±8.06%
GMFI of FcγRIIA on cells 55.57±11.14 86.39±14.90
a
Percentage of cells infected with DENV2 (MOI=0.5) without MAb on day 2 pi.
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